[Form 4] Twist Bioscience Corporation Insider Trading Activity
Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), reported a non-discretionary sale of shares on 08/21/2025 to satisfy tax withholding on vesting restricted stock units. The Form 4 shows a sale of 238 shares at a price of $25.964 per share, leaving the reporting person with 49,542 shares beneficially owned after the transaction. The filing clarifies this was a mandatory "sell to cover" required by the issuer's equity incentive plan and not an independent trading decision by the reporting person.
Robert F. Werner, Chief Accounting Officer di Twist Bioscience Corp (TWST), ha riportato una vendita non discrezionale di azioni il 21/08/2025 per coprire le ritenute fiscali sulle restricted stock unit in scadenza. Il Modulo 4 indica la vendita di 238 azioni al prezzo di $25,964 per azione, lasciando alla persona che ha presentato la comunicazione 49.542 azioni di proprietà effettiva dopo la transazione. Il deposito chiarisce che si è trattato di una vendita obbligatoria "sell to cover" prevista dal piano di incentivazione azionaria dell'emittente e non di una decisione di trading autonoma della persona segnalante.
Robert F. Werner, Director de Contabilidad de Twist Bioscience Corp (TWST), informó una venta no discrecional de acciones el 21/08/2025 para cubrir las retenciones fiscales sobre unidades de acciones restringidas que estaban por consolidarse. El Formulario 4 muestra la venta de 238 acciones a un precio de $25.964 por acción, dejando a la persona informante con 49.542 acciones de propiedad beneficiaria tras la operación. La presentación aclara que fue una "sell to cover" obligatoria exigida por el plan de incentivos de capital de la emisora y no una decisión de negociación independiente del informante.
트위스트 바이오사이언스(TWST)의 최고회계책임자 Robert F. Werner는 2025년 8월 21일 비재량적 주식 매각을 보고했으며, 이는 베스팅되는 제한주식(RSU)에 대한 세금 원천징수를 충당하기 위한 것이었습니다. Form 4에는 주당 $25.964에 238주를 매각한 것으로 기재되어 있으며, 거래 후 보고자는 49,542주의 실질 보유주식을 보유하고 있습니다. 제출서류는 이 매각이 발행회사의 주식 인센티브 계획에 의해 요구된 의무적인 "sell to cover"였으며 보고자의 독자적인 거래 결정이 아님을 분명히 하고 있습니다.
Robert F. Werner, directeur comptable de Twist Bioscience Corp (TWST), a déclaré une cession non discrétionnaire d'actions le 21/08/2025 afin de couvrir les retenues fiscales liées à des restricted stock units arrivant à échéance. Le formulaire 4 indique la vente de 238 actions au prix de 25,964 $ par action, laissant la personne déclarante avec 49 542 actions détenues bénéficiairement après la transaction. le dépôt précise qu'il s'agissait d'une opération obligatoire de type « sell to cover » imposée par le plan d'incitation en actions de l'émetteur et non d'une décision de trading indépendante du déclarant.
Robert F. Werner, Chief Accounting Officer von Twist Bioscience Corp (TWST), meldete am 21.08.2025 einen nicht discretionary Verkauf von Aktien, um Steuerabzüge auf vestende Restricted Stock Units zu begleichen. Das Formular 4 weist den Verkauf von 238 Aktien zu einem Preis von $25,964 pro Aktie aus, wodurch die meldende Person nach der Transaktion 49.542 Aktien wirtschaftlich besitzt. Die Einreichung stellt klar, dass es sich um ein verpflichtendes "sell to cover" handelte, das durch den Aktienvergütungsplan des Emittenten vorgeschrieben ist, und nicht um eine eigenständige Handelsentscheidung der meldenden Person.
- Transaction disclosed promptly on Form 4, demonstrating compliance with Section 16 reporting requirements
- Sale was non-discretionary (a mandatory "sell to cover" for tax withholding), reducing likelihood it signals a change in the officer's view
- Beneficial ownership decreased by 238 shares following the sale
- Filing provides limited context beyond the sell-to-cover explanation (no market commentary or broader compensation detail)
Insights
TL;DR: A routine sell-to-cover transaction by an officer; non-discretionary and limited in size.
The Form 4 documents a sale of 238 shares at $25.964 to satisfy tax withholding on vested RSUs. This type of transaction is common when companies require withholding at vesting and does not indicate a voluntary disposition for cash or a change in investment view. The remaining reported beneficial ownership of 49,542 shares provides context on the officer's continued stake. No derivative transactions or additional material events are reported.
TL;DR: Filing shows compliance with equity-plan withholding rules; no governance red flags evident.
The submission, signed by an attorney-in-fact, notes the sale was mandated by the issuer's election under its equity incentive plans. That clarity supports transparency and adherence to plan terms. There are no indications of rule 10b5-1 trading plans or other arrangements disclosed. The disclosure is narrowly focused and fulfills Section 16 reporting requirements.
Robert F. Werner, Chief Accounting Officer di Twist Bioscience Corp (TWST), ha riportato una vendita non discrezionale di azioni il 21/08/2025 per coprire le ritenute fiscali sulle restricted stock unit in scadenza. Il Modulo 4 indica la vendita di 238 azioni al prezzo di $25,964 per azione, lasciando alla persona che ha presentato la comunicazione 49.542 azioni di proprietà effettiva dopo la transazione. Il deposito chiarisce che si è trattato di una vendita obbligatoria "sell to cover" prevista dal piano di incentivazione azionaria dell'emittente e non di una decisione di trading autonoma della persona segnalante.
Robert F. Werner, Director de Contabilidad de Twist Bioscience Corp (TWST), informó una venta no discrecional de acciones el 21/08/2025 para cubrir las retenciones fiscales sobre unidades de acciones restringidas que estaban por consolidarse. El Formulario 4 muestra la venta de 238 acciones a un precio de $25.964 por acción, dejando a la persona informante con 49.542 acciones de propiedad beneficiaria tras la operación. La presentación aclara que fue una "sell to cover" obligatoria exigida por el plan de incentivos de capital de la emisora y no una decisión de negociación independiente del informante.
트위스트 바이오사이언스(TWST)의 최고회계책임자 Robert F. Werner는 2025년 8월 21일 비재량적 주식 매각을 보고했으며, 이는 베스팅되는 제한주식(RSU)에 대한 세금 원천징수를 충당하기 위한 것이었습니다. Form 4에는 주당 $25.964에 238주를 매각한 것으로 기재되어 있으며, 거래 후 보고자는 49,542주의 실질 보유주식을 보유하고 있습니다. 제출서류는 이 매각이 발행회사의 주식 인센티브 계획에 의해 요구된 의무적인 "sell to cover"였으며 보고자의 독자적인 거래 결정이 아님을 분명히 하고 있습니다.
Robert F. Werner, directeur comptable de Twist Bioscience Corp (TWST), a déclaré une cession non discrétionnaire d'actions le 21/08/2025 afin de couvrir les retenues fiscales liées à des restricted stock units arrivant à échéance. Le formulaire 4 indique la vente de 238 actions au prix de 25,964 $ par action, laissant la personne déclarante avec 49 542 actions détenues bénéficiairement après la transaction. le dépôt précise qu'il s'agissait d'une opération obligatoire de type « sell to cover » imposée par le plan d'incitation en actions de l'émetteur et non d'une décision de trading indépendante du déclarant.
Robert F. Werner, Chief Accounting Officer von Twist Bioscience Corp (TWST), meldete am 21.08.2025 einen nicht discretionary Verkauf von Aktien, um Steuerabzüge auf vestende Restricted Stock Units zu begleichen. Das Formular 4 weist den Verkauf von 238 Aktien zu einem Preis von $25,964 pro Aktie aus, wodurch die meldende Person nach der Transaktion 49.542 Aktien wirtschaftlich besitzt. Die Einreichung stellt klar, dass es sich um ein verpflichtendes "sell to cover" handelte, das durch den Aktienvergütungsplan des Emittenten vorgeschrieben ist, und nicht um eine eigenständige Handelsentscheidung der meldenden Person.
FAQ
What did Robert F. Werner report on Form 4 for TWST?
Was the sale by the Twist Bioscience officer discretionary?
How many TWST shares does the reporting person own after the transaction?
Does the Form 4 indicate any derivative transactions or 10b5-1 plan?
Who signed the Form 4 filing for Robert F. Werner?
